Showing 2591-2600 of 7415 results for "".
- A Novel Dual-Wavelength, Nd:YAG, Picosecond-domain Laser Safely and Effectively Removes Multicolor Tattooshttps://practicaldermatology.com/news/a-novel-dual-wavelength-ndyag-picosecond-domain-laser-safely-and-effectively-removes-multicolor-tattoos/2458848/Research conducted by Eric F. Bernstein MD, MSc; Kevin T. Schomacker PhD; Lisa D. Basilavecchio RN; Jessica M. Plugis; and Jayant D. Bhawalkar PhD, published in the September 2015 issue of Lasers in Surgery and Medicine (LSM), evaluated 21 tattooed subjects between the ages of 19-55 who
- Teledermoscopy Speeds Time to Case Resolution. In Australiahttps://practicaldermatology.com/news/teledermoscopy-speeds-time-to-case-resolution-in-australia/2457768/Teledermatology for skin cancer referral and triage would add to the costs of care but would result in more rapid clinical resolution&m
- Humira Talking Pen Launched to Educate on Self-injectionhttps://practicaldermatology.com/news/20120917-humira_talking_pen_launched_to_educate_on_self-injection/2459737/Abbott Laboratories, makers of Humira, released the Humira Talking Training Pen, available at no cost as part of the myHUMIRA patient support program (humira.com/m
- Cyndi Lauper to Host New Novartis PsO Podcasthttps://practicaldermatology.com/news/cyndi-lauper-to-host-new-novartis-pso-podcast/2460514/Novartis is launching PsO in the Know, a podcast series hosted by music icon Cyndi Lauper. PsO in the Know will feature a variety of guests, including Chef Aarón Sánchez, actress and New York Times best-selling author La La Anthony, and Emmy
- Sunscreen Chemicals Found in the Bloodstream: Experts React to the New Findingshttps://practicaldermatology.com/news/sunscreen-chemicals-found-in-bloodstream-experts-react-to-the-new-findings/2460023/Several active ingredients found in different sunscreens enter the bloodstream at levels that far exceed the FDA's recommended threshold without a government safety inspection, a new study in Journal of the American M
- Sensus Healthcare Launches SRT-100 for Keloid Prevention and Treatment in Chinahttps://practicaldermatology.com/news/sensus-healthcare-launches-srt-100-in-china-for-keloid-prevention-and-treatment/2457985/Sensus Healthcare, Inc. launched the SRT-100™ in China for the treatment and prevention of keloids with Chindex Medical Limited. Sensus also announced the extension of its exclusive distribution agreement with Chindex M
- Candescent Partners Buys Dermatology Associates of Tylerhttps://practicaldermatology.com/news/20130114-candescent_partners_buys_dermatology_associates_of_tyler/2459638/Candescent Partners, a Boston-based private equity firm, acquired Dermatology Associates of Tyler. Candescent led the transaction with co-investors Eagle Private Capital and Harbert Mezzanine Partners. Dermatology Associates provides m
- Dr. Siegel Discusses Sedation Without Drugshttps://practicaldermatology.com/news/Dr-Siegel-Discusses-Sedation-Without-Drugs/2471217/A significant portion of today’s patient population is interested in all-natural alternatives to drugs when possible, and sedation is an area where some useful options exist, according to Daniel M. Siegel, MD. “Sedation without drugs [is important] if you have new-age patients or, I guess,
- Neurotrimin Identified as Key Target for Keloid Treatment: Analysishttps://practicaldermatology.com/news/neurotrimin-identified-key-target-keloid-treatment-analysis/2470778/Researchers for a new genetic study have identified seven proteins as potential drug targets for the treatment of keloids, with neurotrimin (NTM) emerging as a particularly significant finding. Publishing in the Journal of Investigative Dermatology, the study design employed a two-sample M
- Study: Potential for Combined Laser Treating Vascular and Pigmented Lesionshttps://practicaldermatology.com/news/combined-laser-shows-potential-vascular-and-pigmented-lesions/2462743/A novel laser with cryogen cooling long-pulsed options of both 532nm and 1,064nm laser offers laser surgeons a safe and effective way to treat vascular and pigmented lesions with a single device and significantly different clinical endpoints, wrote Nicole M. Golbari, MD, of the University of Cali